Shopping Cart
- Remove All
Your shopping cart is currently empty
Argentina
Australia
Austria
Belgium
Brazil
Bulgaria
Croatia
Cyprus
Czech
Denmark
Egypt
Estonia
Finland
France
Germany
Greece
Hong Kong
Hungary
Iceland
India
Ireland
Israel
Italy
Japan
Korea
Latvia
Lebanon
Malaysia
Malta
Morocco
Netherlands
New Zealand
Norway
Poland
Portugal
Romania
Singapore
Slovakia
Slovenia
Spain
Sweden
Switzerland
Taiwan,China
Thailand
Turkey
United Kingdom
United States
Other Countries
Select your Country or Region
DHODH-IN-8
Contact us for more batch information
DHODH-IN-8
Catalog No. T11030Cas No. 1148126-03-7
DHODH-IN-8 has antimalarial activity. DHODH-IN-8 is an inhibitor of human and Plasmodium falciparum dihydroorotate dehydrogenase (DHODH) with IC50 of 0.13 μM and 47.4 μM, and Kis of 0.016 μM and 5.6 μM, respectively.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $117 | In Stock | |
| 2 mg | $175 | In Stock | |
| 5 mg | $268 | In Stock | |
| 10 mg | $394 | In Stock | |
| 25 mg | $592 | In Stock | |
| 50 mg | $828 | In Stock | |
| 100 mg | $1,130 | In Stock | |
| 500 mg | Inquiry | In Stock | |
| 1 mL x 10 mM (in DMSO) | $262 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "DHODH-IN-8"
RS 61443
T0245115007-34-6
RS 61443 (Mycophenolate mofetil) is an immunosuppressant, a non-competitive, selective and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH)
- $31
Size
QTY
CBR-5884
T14884681159-27-3
CBR-5884 is an selective, active of phosphoglycerate dehydrogenase (PHGDH) inhibitor with an IC50 of 33 μM. CBR-5884 inhibits de novo serine synthesis in cancer cells and is selectively toxic to cancer cell lines with high serine biosynthetic activity. CBR-5884 selectively inhibits the proliferation of melanoma and breast cancer lines that have a high propensity for serine synthesis. Biochemical characterization of the inhibitor revealed that it was a noncompetitive inhibitor that showed a time-dependent onset of inhibition and disrupted the oligomerization state of PHGDH
- $39
Size
QTY
3-Hydroxybenzaldehyde
T4778100-83-4
3-Hydroxybenzaldehyde is a compound useful in organic synthesis.
- $31
Size
QTY
NCT-502
T162771542213-00-2In house
NCT-502 (N-(4,6-dimethylpyridin-2-yl)-4-[5-(trifluoromethyl)pyridin-2-yl]piperazine-1-carbothioamide) is a human phosphoglycerate dehydrogenase inhibitor, cytotoxic to PHGDH-dependent cancer cells. It decreases glucose-derived serine production and it has an IC50 of 3.7 μM against PHGDH.
- $33
Size
QTY
17β-HSD10-IN-1
T775762316765-78-1
17β-HSD10-IN-1 is an orally available 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10) inhibitor with blood-brain permeability and potency for the study of Alzheimer's disease.
- $68
Size
QTY
Nitrofurazone
Cited
T089759-87-0
Nitrofurazone (Furacilin) is a topical anti-infective agent effective against gram-negative and gram-positive bacteria. It is used for superficial WOUNDS AND INJURIES and skin infections. Nitrofurazone(NFZ) has also been administered orally in the treatment of TRYPANOSOMIASIS.
- $50
Size
QTY
CitedDevimistat
T615795809-78-2
Devimistat (6,8-Bis(benzylthio)octanoic acid) , a lipoate analog, inhibits mitochondrial enzymes pyruvate dehydrogenase (PDH) and α-ketoglutarate dehydrogenase, disrupts tumor cell mitochondrial metabolism. It has potential chemopreventive and antineoplastic activities, and has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Advanced Cancer, and Pancreatic Cancer, among others.
- $53
Size
QTY
Tiazofurin
T4068660084-10-8
Tiazofurin (NSC-286193) is a synthetic nucleoside analogue with antineoplastic activity. Tiazofurin is anabolized intracellularly to tiazole-4-carboxamide adenine dinucleotide (TAD), a potent IMP dehydrogenase (IMPDH) inhibitor.
- $257
Size
QTY
BAY-2402234 Cited
T145012225819-06-5
BAY-2402234 is an inhibitor of dihydroorotate dehydrogenase (DHODH) for the treatment of myeloid malignancies.BAY 2402234 is a selective low-nanomolar inhibitor of human DHODH enzymatic activity.
- $183
Size
QTY
CitedCAY10566
T14878944808-88-2
CAY10566 shows excellent cellular activity in blocking the conversion of saturated long-chain fatty acid-CoAs (LCFA-CoAs) to monounsaturated LCFA-CoAs in HepG2 cells (IC50=7.9 nM or 6.8 nM). CAY10566 is a potent, orally bioavailable and selective stearoyl
- $47
Size
QTY
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | DHODH-IN-8 has antimalarial activity. DHODH-IN-8 is an inhibitor of human and Plasmodium falciparum dihydroorotate dehydrogenase (DHODH) with IC50 of 0.13 μM and 47.4 μM, and Kis of 0.016 μM and 5.6 μM, respectively. |
| In vitro | Dihydroorotic acid dehydrogenase (DHODH) is an attractive chemotherapeutic target among various pathogens, such as Plasmodium falciparum and Helicobacter pylori, and is used to treat human diseases. DHODH catalyzes the conversion of dihydroorotate (DHO) to orotate by using the FMN cofactor in the only redox reaction present in the pyrimidine biosynthesis pathway. Human DHODH (HsDHODH)a and Plasmodium falciparum DHODH (PfDHODH) are both DHODHs using respiratory quinones as terminal electron acceptors[1]. |
| Molecular Weight | 312.75 |
| Formula | C17H13ClN2O2 |
| Cas No. | 1148126-03-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 55 mg/mL (175.86 mM)  | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。 Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Dose Conversion
You can also refer to dose conversion for different animals. More
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.